Additional Relevant Details Seattle Genetics will receive a one-time $20 million milestone payment under its ADCETRIS (brentuximab vedotin) collaboration withTakeda Pharmaceutical Company Limited (Takeda). The milestone was triggered by Takeda surpassing annual ADCETRIS net sales of $200 million in its territory during 2015. The milestone will be recognized as royalty revenue in the first quarter of 2016. In addition, the company announced that the European Commission recently approved a Type II variation that includes data on the retreatment of adult patients with relapsed or refractory (R/R) Hodgkin lymphoma or R/R systemic anaplastic large cell lymphoma (sALCL) who previously responded to ADCETRIS and who later relapse.